Beyond Isotretinoin: New Review Explores the Evolving Landscape of Systemic Acne Therapy

A new narrative review provided a comprehensive update on emerging systemic therapies for moderate to severe acne, emphasizing alternatives to isotretinoin in response to its well-known safety limitations.¹ Although isotretinoin remains the most effective therapy for severe acne, its teratogenicity, mucocutaneous adverse effects, and need for intensive monitoring continue to drive the search for safer, targeted options.²

Targeted Antimicrobials and Low-Cost Alternatives

Among newer systemic antibiotics, sarecycline represents a notable advance. As a narrow-spectrum tetracycline, it demonstrates significant reductions in inflammatory lesions as early as 3 weeks, with sustained improvement through 12 weeks in phase 3 trials. Importantly, its selective antimicrobial activity minimizes disruption of the gut microbiome and reduces risks such as phototoxicity, supporting its role as an antibiotic stewardship–aligned option. Oral zinc is also emerging as a low-cost alternative with anti-inflammatory and antimicrobial properties, showing noninferiority to lymecycline in some studies without contributing to antibiotic resistance.

Hormonal and Metabolic Interventions

Beyond antimicrobials, hormonal therapies remain a cornerstone for women with androgen-driven acne. Spironolactone has demonstrated robust efficacy across randomized trials and meta-analyses, significantly reducing lesion counts and improving quality of life, often outperforming doxycycline in adult women. Combined oral contraceptives offer comparable efficacy to oral antibiotics by 6 months, though their use is limited by thromboembolic risk in select populations. Metformin, although not a novel agent, is increasingly recognized for its utility in patients with polycystic ovary syndrome or insulin resistance. By reducing IGF-1 and androgen levels, it improves acne outcomes both as monotherapy and adjunctive treatment, highlighting the importance of targeting metabolic drivers in selected patients.

Immunomodulatory and Anti-Inflammatory Strategies

The review also underscored acne’s immunologic underpinnings, which have prompted investigation into biologic and immunomodulatory therapies. Agents such as adalimumab and interleukin inhibitors have shown benefit in severe, refractory cases such as acne conglobata and SAPHO syndrome, although evidence is currently limited to case reports and small series. Notably, controlled trials of IL-17 inhibition have yielded mixed results.

PDE-4 inhibition with apremilast represents another emerging anti-inflammatory strategy, with case-based evidence demonstrating efficacy in acne fulminans and refractory syndromic presentations. Similarly, montelukast, a leukotriene receptor antagonist, has shown comparable efficacy to doxycycline in small studies and may enhance outcomes when used in combination regimens, although larger trials are needed to confirm its role.

The Gut-Skin Axis and Experimental Options

Microbiome-targeted approaches are also gaining traction, according to the review. Oral probiotics have demonstrated the ability to reduce inflammatory lesions, sebum production, and cytokine activity, particularly when used adjunctively with standard therapies. These findings support a growing appreciation of the gut-skin axis in acne pathogenesis, although variability in probiotic strains and study designs limits standardization and widespread adoption.

At the experimental frontier, vaccine-based strategies targeting Cutibacterium acnes virulence factors, such as CAMP factor, offer a novel mechanism to reduce bacterial pathogenicity without disrupting commensal flora. Although promising in preclinical models, these approaches remain investigational, and their long-term safety still requires further study.

Clinical Implications

Despite these advances, the review highlights several limitations across the emerging therapeutic landscape. Most alternative systemic therapies lack direct, head-to-head comparisons with isotretinoin, making it difficult to position them within treatment algorithms. Additionally, many therapies, particularly biologics and immunomodulators, are supported by limited evidence and face practical barriers, including high cost, off-label status, and restricted access. Even well-supported options such as spironolactone and metformin remain underutilized in some settings due to regulatory and prescribing constraints.

Rather than a one-size-fits-all approach, emerging therapies enable clinicians to tailor treatment based on underlying pathophysiology, including hormonal, metabolic, inflammatory, and microbiome-related factors. Although isotretinoin continues to set the benchmark for efficacy, alternative systemic therapies offer meaningful benefits in select patient populations, particularly those who cannot tolerate or should avoid retinoids. Future research priorities include large-scale randomized controlled trials, comparative effectiveness studies, and the development of validated biomarkers to guide therapy selection.

References

1. Tommasino N, Annunziata MC, Potestio L, Napolitano M. Beyond isotretinoin: a narrative review of emerging systemic therapies for moderate-to-severe acne. J Cosmet Dermatol. 2026;25(4):e70812. doi:10.1111/jocd.70812

2. Huang CY, Chang IJ, Bolick N, et al. Comparative efficacy of pharmacological treatments for acne vulgaris: a network meta-analysis of 221 randomized controlled trials. Ann Fam Med. 2023;21(4):358-369. doi:10.1370/afm.2995